CN115887564B - Composition for prophylactic treatment of headache and preparation method thereof - Google Patents
Composition for prophylactic treatment of headache and preparation method thereof Download PDFInfo
- Publication number
- CN115887564B CN115887564B CN202211682552.6A CN202211682552A CN115887564B CN 115887564 B CN115887564 B CN 115887564B CN 202211682552 A CN202211682552 A CN 202211682552A CN 115887564 B CN115887564 B CN 115887564B
- Authority
- CN
- China
- Prior art keywords
- composition
- volatile oil
- water
- roasted
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 206010019233 Headaches Diseases 0.000 title claims abstract description 37
- 231100000869 headache Toxicity 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000011321 prophylaxis Methods 0.000 title claims description 20
- 239000000341 volatile oil Substances 0.000 claims abstract description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 15
- 239000004863 Frankincense Substances 0.000 claims abstract description 14
- 244000150195 Cyperus longus Species 0.000 claims abstract description 12
- 238000003809 water extraction Methods 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 238000001556 precipitation Methods 0.000 claims abstract description 10
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 9
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 9
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 9
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 9
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 8
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 8
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 7
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 7
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 7
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 7
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 7
- 229940107666 astragalus root Drugs 0.000 claims abstract description 7
- 235000005412 red sage Nutrition 0.000 claims abstract description 7
- 241001057584 Myrrha Species 0.000 claims abstract description 6
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 5
- 230000001376 precipitating effect Effects 0.000 claims abstract description 5
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 4
- 241000601164 Clematis orientalis Species 0.000 claims abstract description 4
- 241000218158 Clematis Species 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 239000001116 FEMA 4028 Substances 0.000 claims description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 229960004853 betadex Drugs 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000903946 Clematidis Species 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 241000628997 Flos Species 0.000 claims description 3
- 241000112528 Ligusticum striatum Species 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 abstract description 14
- 206010027599 migraine Diseases 0.000 abstract description 14
- 230000003449 preventive effect Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000000037 effect on migraine Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 235000018109 Cyperus longus Nutrition 0.000 abstract 2
- 244000075634 Cyperus rotundus Species 0.000 abstract 2
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 2
- 241000700159 Rattus Species 0.000 description 24
- 239000000243 solution Substances 0.000 description 15
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 11
- 102400000096 Substance P Human genes 0.000 description 11
- 101800003906 Substance P Proteins 0.000 description 11
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 10
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000003128 head Anatomy 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 208000008548 Tension-Type Headache Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 and the high Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for preventing and treating headache and a preparation method thereof, belonging to the field of traditional Chinese medicines. The composition consists of two parts: 1) Volatile oil inclusion compound: volatile oil clathrate of Olibanum, myrrha, rhizoma Cyperi, and rhizoma Ligustici Chuanxiong; 2) Extracting with water and precipitating with ethanol to obtain extract: the water extraction and alcohol precipitation extracts of the roasted nutgrass galingale rhizome, the szechuan lovage rhizome, the Chinese angelica, the red sage root, the Chinese clematis, the roasted astragalus root and the safflower. Wherein, 200-300g of angelica, 400-600g of red sage root, 120-180g of prepared frankincense, 120-180g of prepared myrrh, 300-450g of szechuan lovage rhizome, 240-360g of prepared nutgrass galingale rhizome, 300-450g of clematis root, 300-450g of prepared astragalus root and 200-300g of safflower. The composition provided by the invention has preventive treatment effect on migraine, and can effectively relieve clinical symptoms of migraine.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and in particular relates to a composition for preventive treatment of headache and a preparation method thereof.
Background
The disclosure of this background section is only intended to increase the understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art.
Headache is a clinically common symptom and will generally be localized to the upper part of the skull, including the arch of the eyebrow, the upper edge of the auricle and the pain above the occipital protuberance line, collectively referred to as headache. The causes of headache are numerous and can be broadly divided into primary and secondary. The former cannot be attributed to a certain exact etiology, and can also be called idiopathic headache, such as migraine and tension headache; the latter etiology may involve various intracranial lesions such as cerebrovascular diseases, intracranial infections, craniocerebral trauma, systemic diseases such as fever, internal environmental disorders, abuse of psychoactive drugs, etc. The headache referred to by the invention mainly refers to primary headache such as migraine, tension type headache, angioneurotic headache and the like.
At present, the cause of migraine is not clear, western medicines are mainly used for treatment, the symptoms and root causes are not cured although the medicines relieve the symptoms to a certain extent, long-term medicine taking is usually required, once the medicine is stopped, headache symptoms can be generated, if the medicine is improperly taken, the illness state can be invalid or even aggravated, the toxic and side effects of the western medicines are large, especially, the influence on liver and kidney functions is the greatest, the illness state is repeated, and the side effects of the medicines bring great pain to patients.
Disclosure of Invention
In order to solve the defects of the prior art, the invention aims to provide a composition for preventing and treating migraine and a preparation method thereof.
In order to achieve the above purpose, the technical scheme of the invention is as follows:
The invention provides a composition for the prophylactic treatment of headache, which comprises the following raw materials in parts by weight: 200-300g of angelica, 400-600g of red sage root, 120-180g of roasted frankincense, 120-180g of roasted myrrh, 300-450g of szechuan lovage rhizome, 240-360g of roasted nutgrass galingale rhizome, 300-450g of clematis root, 300-450g of roasted astragalus root and 200-300g of safflower.
Preferably, the composition comprises the following raw materials in parts by weight: 200g of Chinese angelica, 400g of red sage root, 120g of prepared frankincense, 120g of prepared myrrh, 300g of szechuan lovage rhizome, 240g of prepared nutgrass galingale rhizome, 300g of Chinese clematis root, 300g of prepared astragalus root and 200g of safflower.
Preferably, the composition is a tablet, capsule, granule or enteric-coated formulation.
Further preferably, the preparation method of the granule comprises the following steps: adding 3 times of sugar powder into the composition, granulating, and packaging into granule.
In a second aspect of the present invention, there is provided a method for preparing the above composition for prophylactic treatment of headache, comprising the steps of:
s1, extracting volatile oil from roasted frankincense, roasted myrrh, roasted nutgrass galingale rhizome and szechuan lovage rhizome, and preparing volatile oil inclusion compound;
s2, extracting angelica, radix salviae miltiorrhizae, radix clematidis, radix astragali preparata and safflower with water, and precipitating with ethanol to obtain a water extraction and alcohol precipitation extract;
s3, mixing the water extraction and alcohol precipitation extract with the volatile oil inclusion compound, and drying to obtain the water extraction and alcohol precipitation volatile oil inclusion compound.
The processed olibanum and the processed myrrh contain a large amount of volatile oil, the volatile oil has the effects of relieving pain and easing pain, and the rest components mainly comprise resin and gum, have no drug effect and have extremely bad taste. Ligusticum wallichii mainly treating cerebral headache due to apoplexy, enriching blood, treating blood deficiency headache, containing volatile oil, the volatile oil has tranquilization effect on brain. The prepared nutgrass galingale rhizome has the effects of regulating qi, resolving depression, relieving pain and regulating menstruation, and the medicine finds that the prepared nutgrass galingale rhizome has strong analgesic effect, and the volatile oil is rich in various components. Extracting volatile oil from Olibanum, myrrha, rhizoma Ligustici Chuanxiong, and rhizoma Cyperi; the other medicinal materials are extracted into active ingredients by adopting a water extraction and alcohol precipitation process.
Preferably, the extracting steps of the volatile oil are as follows: collecting volatile oil from Olibanum and Myrrha by steaming;
soaking rhizoma Ligustici Chuanxiong and rhizoma Cyperi preparata in 6-8 times of water for 30-50min, extracting for 4-6 hr, collecting volatile oil, and collecting extractive solution.
Preferably, the specific steps for preparing the volatile oil inclusion compound are as follows: mixing purified water and beta-cyclodextrin in a container, stirring, adding into colloid mill, adding volatile oil under grinding, clathrating for 30-45 min, collecting condensed water, and controlling clathrating temperature between 30-40deg.C.
Further preferably, the mass ratio of beta-cyclodextrin to volatile oil is 10:1.
Preferably, the specific steps of water extraction and alcohol precipitation are as follows: extracting radix Angelicae sinensis, saviae Miltiorrhizae radix, radix Clematidis, and radix astragali Preparata with water twice, wherein the first time is 6-8 times of the mass of water for 2-4 hr, the second time is adding Carthami flos, and the second time is 6-8 times of the mass of water for 1-2 hr;
mixing the extractive solutions, concentrating under reduced pressure to relative density of 1.1 at 60deg.C, adding 3-4 times of ethanol, standing for 12-15 hr, collecting supernatant, and recovering ethanol to obtain water-extracted ethanol-precipitated extract.
Further preferably, when the extracts are combined, the liquid medicine obtained by extracting volatile oil from the ligusticum wallichii and the roasted rhizoma cyperi in the step S1 is combined with the extract obtained by extracting the volatile oil from the rhizoma ligustici wallichii and the roasted rhizoma cyperi with water twice.
The beneficial effects of the invention are as follows:
the composition for the prophylactic treatment of the migraine has the prophylactic treatment effect on the migraine, can effectively relieve clinical symptoms of the migraine, and is safe and free from toxic and side effects. The content of CGRP and SP is regulated to inhibit neurogenic vasodilation and plasma protein extravasation, so that neurogenic inflammation is reduced, and a preventive treatment effect on migraine is generated.
Detailed Description
In order to enable those skilled in the art to more clearly understand the technical scheme of the present invention, the technical scheme of the present invention will be described in detail with reference to specific embodiments.
Example 1
A method of preparing a composition for prophylactic treatment of headache comprising the steps of:
Prescription:
The composition consists of two parts:
(1) Volatile oil inclusion compound: volatile oil clathrate of Olibanum, myrrha, rhizoma Cyperi, and rhizoma Ligustici Chuanxiong;
(2) Extracting with water and precipitating with ethanol to obtain extract: the water extraction and alcohol precipitation extracts of the roasted nutgrass galingale rhizome, the szechuan lovage rhizome, the Chinese angelica, the red sage root, the Chinese clematis, the roasted astragalus root and the safflower.
1. Volatile oil clathrate
(1) Collecting volatile oil from Olibanum and Myrrha by steaming, and collecting volatile oil.
(2) Soaking rhizoma Ligustici Chuanxiong and rhizoma Cyperi preparata in 8 times of water for 30min, extracting for 4 hr, collecting volatile oil, and extracting medicinal liquid.
(3) Clathrating the volatile oil of the two parts: mixing purified water and beta-cyclodextrin (beta-cyclodextrin: volatile oil mass ratio of 10:1), stirring, adding into colloid mill, adding volatile oil under grinding for 30-45 min, collecting condensed water, and controlling inclusion temperature between 30-40deg.C to obtain volatile oil clathrate.
2. Water extracting and alcohol precipitating extract
Extracting radix Angelicae sinensis, saviae Miltiorrhizae radix, radix Clematidis, and radix astragali Preparata with 8 times of water for 2 hr, adding Carthami flos for the second water extraction, and extracting with 6 times of water for 1 hr.
Mixing the two extractive solutions with the medicinal liquid of rhizoma Ligustici Chuanxiong and rhizoma Cyperi preparata obtained in the preparation process of "1 and volatile oil clathrate", concentrating under reduced pressure to relative density of 1.1 (60deg.C), adding 3 times of ethanol, standing for 12 hr, collecting supernatant, and recovering ethanol.
Mixing the water extract and the volatile oil clathrate, and drying to obtain the composition for preventing and treating headache.
Application example 1
Study of the efficacy of the composition for prophylactic treatment of headache obtained in example 1
1. Material
1.1 Animals
SPF-class Wistar rats 60, male and female, and the mass is 180-220 g.
1.2 Drugs and Agents
The composition for the prophylactic treatment of headache obtained in example 1 was nitroglycerin, SP enzyme-linked immunosorbent assay kit, enzyme-linked immunosorbent assay kit.
1.3 Major instrumentation
The Synergy enzyme label instrument is Biotech; low temperature high speed centrifuge Sigma; ultra-low temperature refrigerator Sanyo.
2. Medicine preparation
2.1 Preparation of a composition solution for treating headache:
Taking 20mg of the composition for preventing and treating headache obtained in the example 1, dissolving with a small amount of deionized water, uniformly mixing, transferring and fixing the volume to a 100mL volumetric flask, and preparing 0.2g/mL of the composition for preventing and treating headache obtained in the example 1, thereby obtaining a liquid medicine of a dosage group in a composition solution for preventing and treating headache. The concentration of the high-dose group liquid medicine of the composition solution for the prophylactic treatment of the headache is 0.4g/mL, the concentration of the low-dose group liquid medicine of the composition solution for the prophylactic treatment of the headache is 0.1g/mL, and the prepared solution is placed in a refrigerator at the temperature of 4 ℃ for refrigeration for standby, and is preheated for 30min to normal temperature before stomach filling.
2.2 Preparation of a Sibirling solution:
Taking 5mg of the xibeline particles, dissolving with a small amount of deionized water, uniformly mixing, transferring and fixing the volume to a 100mL volumetric flask, and preparing 0.05g/L of the xibeline solution. And (5) placing the prepared solution in a refrigerator at the temperature of 4 ℃ for refrigeration for standby.
3. Experimental grouping and administration
The 60 Wistar rats were randomly grouped into a normal group, a model group, a sibirin group, a high dose group of a composition for prophylactic treatment of headache (i.e., a high dose group), a medium dose group of a composition for prophylactic treatment of headache (i.e., a medium dose group), and a low dose group of a composition for prophylactic treatment of headache (i.e., a low dose group), each group of 10 animals. After 7d of adaptive feeding, each group of rats was subjected to drug intervention. Normal group and model group rats were perfused with normal saline, the sibirin group rats were perfused with 0.05g/L sibirin solution, and the high, medium and low dose groups rats were perfused with 0.4, 0.2 and 0.1g/mL of the composition solution for prophylactic treatment of headache, respectively. The stomach was irrigated with a volume of 10mL/kg 2 times daily for 7 days.
4. Migraine model preparation
After the last administration for 30min, the model group, the Xibling group, and the high, medium and low dosage groups are injected with the nitroglycerin injection (10 mg/kg) to prepare the model, and when the rats have the behaviors of reddening ears, frequent bending of the forelimbs, increased climbing cages and the like, the nitroglycerin model is successfully molded. Normal rats were injected with an equal volume of physiological saline at the neck.
5. Observation index and measurement
5.1 Behavioral observations
1) Rat ear red phenomenon: after molding, the time at which the ear red phenomenon occurred and the time at which the ear red phenomenon subsided were recorded for each group of rats were recorded and observed.
2) Rat deflection head phenomenon: after molding, the rats were recorded and observed for the number of flexible heads per time period for 1 time period of 30 min. The total number of flexible heads was recorded for each group of rats, for a total of 3 hours, by continuously observing 6 time periods.
5.2 Plasma CGRP, SP content detection: after molding for 4 hours, 20% uratam (5 mL/kg) was injected intraperitoneally to anesthetize the rats. Taking 5mL of abdominal aortic blood, injecting into a blood collection tube, uniformly mixing, standing on ice for 2h, placing the blood collection tube into a precooled 4 ℃ low-temperature high-speed centrifuge (3 000r/min,15 min), centrifuging, sucking the supernatant, sub-packaging into a centrifuge tube, and placing into a refrigerator at-80 ℃ for freezing storage for later use. After thawing, the content of Calcitonin Gene Related Peptide (CGRP) and Substance P (SP) is detected by ELISA method, and the operation steps are strictly carried out according to the instruction of ELISA kit.
6. Statistical methods: experimental data are expressed as mean.+ -. Standard deviation (x.+ -. S) using SPSS 21.0 statistical software analysis. The comparison between the multiple groups of the mean values adopts a single factor variance (One-way ANOVA) analysis, and the multiple comparison between the groups adopts an LSD method. P < 0.05 indicates that the difference is statistically significant.
7. Results
7.1 Comparison of the number of deflection heads of rats in each group, see Table 1
TABLE 1 comparison of flex times in each time period for rats of each groupSecondary times
Note that: compared with the normal group, #P < 0.05; comparison with model group P < 0.05
7.2 Comparison of ear reds of rats in each group with appearance and disappearance times of flex heads, see Table 2
TABLE 2 comparison of ear reds and flex head appearance and disappearance times for rats of each groupmin)
Note that: compared with the model group, P < 0.05, P < 0.01
7.3 Comparison of the plasma calcitonin Gene-related peptide (CGRP) and Substance P (SP) content of rats of each group, see Table 3
TABLE 1 comparison of flex times in each time period for rats of each groupng/L)
Note that: compared with the normal group, the # P is less than 0.05, and the # P is less than 0.01; comparison with model group P < 0.05, P < 0.01
From the above, the composition for treating headache by preventive administration can effectively shorten the time required for eliminating ear red of rats in migraine model, and reduce the number of times of deflection of rats in migraine model, which indicates that the composition for treating headache by preventive administration has preventive treatment effect on rats in migraine model, and can effectively relieve clinical symptoms of rats in migraine model.
Comparison with the model group shows that: the content of CGRP and SP in rats with various dosage solutions of the composition for preventive gastric administration of the sibirin solution and the composition for preventive treatment of headache is obviously reduced; the composition for the preventive treatment of headache with high, medium and low doses has the same pharmacological action as the sibirimate, and can reduce the CGRP and SP contents of rats; the high dose group effect was most pronounced, demonstrating that lowering plasma CGRP, SP levels is a possible mechanism for prophylactic treatment of migraine with compositions that prophylactically treat headache.
In summary, the composition for the prophylactic treatment of headache obtained in example 1 may have prophylactic treatment effect on migraine by controlling CGRP and SP content, and inhibiting neurogenic vasodilation and plasma protein extravasation, thereby reducing neurogenic inflammation.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. The composition for the prophylactic treatment of headache is characterized by comprising the following raw materials in parts by weight: 200-300g of angelica, 400-600g of red sage root, 120-180g of roasted frankincense, 120-180g of roasted myrrh, 300-450g of szechuan lovage rhizome, 240-360g of roasted nutgrass galingale rhizome, 300-450g of clematis root, 300-450g of roasted astragalus root and 200-300g of safflower;
the preparation method of the composition for the prophylactic treatment of headache comprises the following steps:
s1, extracting volatile oil from roasted frankincense, roasted myrrh, roasted nutgrass galingale rhizome and szechuan lovage rhizome, and preparing volatile oil inclusion compound;
s2, extracting angelica, radix salviae miltiorrhizae, radix clematidis, radix astragali preparata and safflower with water, and precipitating with ethanol to obtain a water extraction and alcohol precipitation extract;
s3, mixing the water extraction and alcohol precipitation extract with the volatile oil inclusion compound, and drying to obtain the volatile oil inclusion compound;
The preparation method of the volatile oil inclusion compound comprises the following specific steps: mixing purified water and beta-cyclodextrin in a container, stirring, adding into colloid mill, adding volatile oil under grinding, clathrating for 30-45 min, collecting condensate water, and controlling clathrating temperature between 30-40deg.C;
The water extraction and alcohol precipitation steps comprise: extracting radix Angelicae sinensis, saviae Miltiorrhizae radix, radix Clematidis, and radix astragali Preparata with water twice, wherein the first time is 6-8 times of the mass of water for 2-4 hr, the second time is adding Carthami flos, and the second time is 6-8 times of the mass of water for 1-2 hr;
mixing the extractive solutions, concentrating under reduced pressure to relative density of 1.1 at 60deg.C, adding 3-4 times of ethanol, standing for 12-15 hr, collecting supernatant, and recovering ethanol to obtain water-extracted ethanol-precipitated extract.
2. The composition of claim 1, wherein the composition comprises the following raw materials in parts by weight: 200g of Chinese angelica, 400g of red sage root, 120g of prepared frankincense, 120g of prepared myrrh, 300g of szechuan lovage rhizome, 240g of prepared nutgrass galingale rhizome, 300g of Chinese clematis root, 300g of prepared astragalus root and 200g of safflower.
3. The composition of claim 1, wherein the composition is in the form of a tablet, capsule, granule, or enteric formulation.
4. A composition according to claim 3, wherein the granule is prepared by the process of: adding 3 times of sugar powder into the composition, granulating, and packaging into granule.
5. The composition of claim 1, wherein the volatile oil extraction specific steps are: collecting volatile oil from Olibanum and Myrrha by steaming;
soaking rhizoma Ligustici Chuanxiong and rhizoma Cyperi preparata in 6-8 times of water for 30-50min, extracting for 4-6 hr, collecting volatile oil, and collecting extractive solution.
6. The composition of claim 1, wherein the mass ratio of beta-cyclodextrin to volatile oil is 10:1.
7. The composition according to claim 1, wherein the liquid medicine obtained by extracting volatile oil from Ligusticum wallichii and nutgrass galingale rhizome in step S1 is combined with the liquid extract obtained by extracting with water twice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211682552.6A CN115887564B (en) | 2022-12-26 | 2022-12-26 | Composition for prophylactic treatment of headache and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211682552.6A CN115887564B (en) | 2022-12-26 | 2022-12-26 | Composition for prophylactic treatment of headache and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115887564A CN115887564A (en) | 2023-04-04 |
| CN115887564B true CN115887564B (en) | 2024-04-26 |
Family
ID=86482294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211682552.6A Active CN115887564B (en) | 2022-12-26 | 2022-12-26 | Composition for prophylactic treatment of headache and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115887564B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814260A (en) * | 2005-12-14 | 2006-08-09 | 辽宁华源本溪三药有限公司 | Chinese medicine for treating blood stagnation disease |
| CN101357161A (en) * | 2008-08-22 | 2009-02-04 | 江红旗 | External medicine for treating vascular headache and preparation method thereof |
| CN111375035A (en) * | 2018-12-29 | 2020-07-07 | 辽宁上药好护士药业（集团）有限公司 | Preparation and application of enteric-coated preparation for treating cervical spondylosis |
-
2022
- 2022-12-26 CN CN202211682552.6A patent/CN115887564B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814260A (en) * | 2005-12-14 | 2006-08-09 | 辽宁华源本溪三药有限公司 | Chinese medicine for treating blood stagnation disease |
| CN101357161A (en) * | 2008-08-22 | 2009-02-04 | 江红旗 | External medicine for treating vascular headache and preparation method thereof |
| CN111375035A (en) * | 2018-12-29 | 2020-07-07 | 辽宁上药好护士药业（集团）有限公司 | Preparation and application of enteric-coated preparation for treating cervical spondylosis |
Non-Patent Citations (2)
| Title |
|---|
| 杨清华.桂派名老中医 学术卷 李锡光.中国中医药出版社,2021,105-113. * |
| 瘀血痹片质量标准研究;周雪梅;;亚太传统医药;-(12);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115887564A (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068682A (en) | Chinese medicinal composition for treating digestive system diseases and preparation method thereof | |
| CN115887564B (en) | Composition for prophylactic treatment of headache and preparation method thereof | |
| WO2023088488A1 (en) | Traditional chinese medicine composition for preventing and treating brain diseases, preparation method therefor, and application thereof | |
| CN111437338A (en) | Application of traditional Chinese medicine composition in treating skin diseases | |
| CN101433593A (en) | Compound Chinese medicine preparation for treating cardiovascular disease and preparation method thereof | |
| CN102600370A (en) | Application of Chinese medicinal composition in preparing medicament for preventing and treating Parkinsonism | |
| CN110123974A (en) | A kind of composition that treating hyperuricemia and preparation method | |
| CN116173177A (en) | Pharmaceutical composition for continuously improving male sexual function and preparation method thereof | |
| CN113384609A (en) | Application of Shanxi American ginseng in forest in preparing medicine for treating antibiotic-associated diarrhea | |
| CN105031033B (en) | Blood sugar reducing pharmaceutical composition containing boxthorn leaves and preparation method and application thereof | |
| CN102335345B (en) | Chinese medicinal composition for nourishing yin, clearing heat, and moistening lung for arresting cough, and its preparation method | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN118286310B (en) | Application of nux Prinsepiae or extract and composition thereof in treating and/or preventing liver injury | |
| CN108704105A (en) | A kind of Chinese medicine composition for treating Acute Cerebral Infarction | |
| CN114470130B (en) | Traditional Chinese medicine composition for treating cardiac neurosis and application thereof | |
| CN109568463A (en) | A kind of Antidiarrheal Chinese medicine composition and its preparation method and application | |
| CN117442677B (en) | Pharmaceutical composition for kidney injury and preparation method and application thereof | |
| CN116251141B (en) | Traditional Chinese medicine composition for dispelling wind-cold and preparation method and application thereof | |
| CN115715784B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis, application and pharmaceutical preparation thereof | |
| CN114272354B (en) | Traditional Chinese medicine composition for preventing and improving senile dementia, preparation method and application thereof | |
| CN111419920B (en) | Medicine composition with hypoglycemic effect and preparation method and application thereof | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN116785395A (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating bacterial pneumonia | |
| CN118001350A (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating bacterial pneumonia | |
| CN107684594B (en) | Kidney-tonifying pharmaceutical composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |